Protein degradation and drug discovery by Monte Rosa Therapeutics
Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects
Monte Rosa Therapeutics announced plans to present results from GFORCE-1, its Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease risk. The company highlighted its ...
Monte Rosa Therapeutics launches patient dosing in MRT-2359 combination study for mCRPC
Monte Rosa Therapeutics has initiated patient dosing in its Phase 2 MODeFIRe-1 clinical trial. The study is evaluating MRT-2359 in combination with apalutamide for patients with androgen receptor ...
Monte Rosa Therapeutics delivers second quarter financial results and advances pipeline momentum
Monte Rosa Therapeutics has released its financial results and business update for the second quarter 2026. Chief Executive Officer Markus Warmuth shared insights into the company’s ...
Precision oncology approach for CCNE1-altered cancers advances with new data, Monte Rosa Therapeutics reports
Monte Rosa Therapeutics presented preclinical data on its highly selective CCNE1-targeting molecular glue degrader this week at AACR D3. The research, led by Nina Ilic-Widlund and Bill Tahaney, ...
Monte Rosa Therapeutics unveils MRT-6160 preclinical data showing disease inhibition in immune models
Monte Rosa Therapeutics revealed new preclinical findings for MRT-6160 at the Newcastle International Therapeutic Tolerance Workshop. The company reported that MRT-6160, a first-in-class VAV1 MGD, ...
Monte Rosa Therapeutics pledges support for LGBTQ employees with focus on authentic workplace culture
Monte Rosa Therapeutics has reaffirmed its dedication to fostering an inclusive work environment where employees do not have to choose between professional advancement and personal authenticity. ...
Monte Rosa Therapeutics advances NEK7-targeted MRT-8102 for cardiovascular disease inflammation
Monte Rosa Therapeutics introduces MRT-8102, a NEK7-directed molecular glue degrader, as a novel strategy in combating cardiovascular disease driven by inflammation. The company’s Chief Medical ...
Monte Rosa Therapeutics advances molecular glue degrader strategy at Jefferies Healthcare Conference
Monte Rosa Therapeutics provided updates on its clinical pipeline and ongoing progress in molecular glue degrader programs during a fireside chat at the Jefferies Global Healthcare Conference in ...
Monte Rosa Therapeutics spotlights molecular glue degraders in treating undruggable proteins
Monte Rosa Therapeutics draws attention to a recent Bloomberg feature exploring the potential of molecular glue degraders for targeting disease-driving proteins previously considered undruggable. ...
IDEA Pharma recognizes Monte Rosa Therapeutics for advancing MGD drug development
Monte Rosa Therapeutics has been recognized as a Disruptive Pioneer by IDEA Pharma in the 2026 Innovation and Invention Index, an annual assessment honoring companies driving groundbreaking ...
Monte Rosa Therapeutics to detail new molecular glue degrader research at Endpoints webinar
Monte Rosa Therapeutics will present its latest research on the versatility of molecular glue degraders during an upcoming Endpoints webinar. The session, featuring Georg Petzold and Chao Quan, ...
Monte Rosa Therapeutics unveils preclinical data on targeting undruggable CCNE1 in solid tumors
Monte Rosa Therapeutics has presented preclinical data at AACR26 regarding its CCNE1-directed molecular glue degrader, aimed at treating CCNE1-amplified solid tumors. The approach suggests a new ...
Monte Rosa Therapeutics CEO to join AACR2026 panel on proximity-induced therapies
Monte Rosa Therapeutics will participate in the AACR2026 conference, with CEO Markus Warmuth set to join a panel of leading biopharma executives focused on proximity-induced therapies. This move ...
